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time of switching also matters for persistence: Switching during
the ﬁrst quarter after the initial statin reduces persistence less 
(-8.4%, p = 0.0073) than switching during the following quar-
ters (-20.7% Q2, -17.2% Q3, -14.6% Q4, p < 0.0001 for all
coefﬁcients). Switching signiﬁcantly reduces the probability of
high compliance deﬁned as MPR° 0.8 (odds ration 0.856) vs.
no switch (p < 0.0001). Finally, atorvastatin users are the least
likely to switch to another statin (odds ratio for probability to
switch vs. atorvastatin: ﬂuvastatin 2.66, pravastatin 2.67, lovas-
tatin 1.54, simvastatin 1.88; p < 0.0001 for all coefﬁcients).
CONCLUSION: Switching lowers both persistence and compli-
ance, speciﬁcally by reducing the number of long-term users.
Patients started on atorvastatin are less likely to be switched to
another statin during the course of their treatment.
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OBJECTIVES: To evaluate inﬂuences of prescription drug
beneﬁt parameters on participant adherence to drug therapies 
for chronic conditions. METHODS: Deidentiﬁed pharmacy
claims were analyzed for participants continuously eligible from
January 1 to December 31, 2003 and treated for diabetes, hyper-
tension or hypercholesterolemia. Participants were grouped
according to plan design: 201,179 diabetics in 666 groups;
535,446 hypercholesterolemia participants in 845 groups; and
877,918 hypertension participants in 940 groups. Based on a
combination of compliance and persistency, average adherence
was calculated for each group. Multivariate linear regression
analyses were performed for the conditions, controlling for
demographics and comorbidities. RESULTS: Analyses showed
consistent effects of plan design parameters on adherence across
the conditions. While major plan design changes intended to
drive mail utilization may cause initial therapy disruption, result-
ing in short-term decreases in adherence (parameter estimate
(PE) between -0.046 and -0.025, p < 0.0001), overall higher
mail utilization improves adherence consistently across condi-
tions (PE between 0.043 and 0.062, p <= 0.0003). Clinical pro-
grams improve adherence for diabetes therapies (PE = 0.017, p
= 0.0001). The effect of co-payment amounts varies with avail-
ability of generic and formulary alternatives for each therapy.
Adherence improves when co-payment amounts lead to
decreased participant cost-share in generic and preferred mail-
order drugs. Adherence improves when generic, formulary and
mail-service cost-share is lower than retail and nonformulary
cost-share. The effect of co-payment amounts is small but mea-
surable and signiﬁcant within 90% conﬁdence interval. Older
populations were more adherent (PE between 0.001 and 0.004,
and p < 0.0001). Female participants exhibited higher adherence
(PE between 0.050 and 0.112, p <= 0.0048). Populations with
higher income have improved adherence to hypercholesterolemia
therapies (PE = 0.00065, p = 0.0001). Populations with comor-
bidities are more adherent (PE between 0.014 and 0.023, p <=
0.0004). CONCLUSIONS: Plan design parameters play an
important role in therapy adherence for chronic conditions.
Effects of plan design parameters persist when accounting for
demographic and comorbidity factors.
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OBJECTIVES: a) To evaluate the relationship of direct-to-
consumer advertising (DTCA) expenditures, health insurance
coverage, age and gender with number of patients diagnosed
with hyperlipidemia; b) To compare the relationships prior to
and following the relaxation of guidelines for broadcast adver-
tising. METHODS: The data sources utilized were Competitive
Media Reporting (CMR) and the National Ambulatory Medical
Care Survey (NAMCS) for the time period January, 1994 to
April, 2001. The monthly DTCA expenditures for antilipemics
were calculated from the CMR dataset. Applying weights to the
NAMCS data yielded national estimates. Using NAMCS, the
monthly frequency of patients diagnosed with hyperlipidemia
(ICD-9 codes) was calculated. Each month, among patients
diagnosed with hyperlipidemia, percentage of individuals 45
years and older, percentage of women and percentage of indi-
viduals with health insurance coverage were calculated. The
dataset was then split into two time periods (January, 1994 to
August, 1997 and September 1997, to April, 2001) to identify
the change in relationships following the relaxation of rules for
broadcast advertising in August 1997. Time series analysis was
conducted to determine which factors were related to number of
patients diagnosed with hyperlipidemia during the entire time
period and the two time periods. RESULTS: Only DTCA expen-
ditures for antilipemics was signiﬁcantly related to the frequency
of patients diagnosed with hyperlipidemia (p < 0.05). For every
$1000 spent on advertising antilipemics, 14 more patients 
were diagnosed with hyperlipidemia. On splitting the dataset,
DTCA expenditures were signiﬁcantly related to number of
patients diagnosed with hyperlipidemia only prior to relaxation
of guidelines (January, 1994 to August, 1997). CONCLUSION:
Although DTCA expenditures were signiﬁcantly related to
number of patients diagnosed with hyperlipidemia during the
entire time period from January, 1994 to April, 2001, on evalu-
ating the relationship prior to and following relaxation of guide-
lines, this relationship was signiﬁcant only prior to the relaxation
of guidelines.
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OBJECTIVES: This study assessed the occurrence and the pre-
dictors of lipid tests and liver function tests (LFTs) among Texas
Medicaid patients on statin therapy. METHODS: A retrospec-
tive cohort analysis using pharmacy and medical claims of new
statin users between September 1, 1999 and August 31, 2001
was done. The presence of lipid and liver function tests (LFTs)
after the start of statin therapy were determined based on the
procedural codes. Logistic regression models were used to assess
the predictors of the occurrence of the tests. Variables in the
model were demographic variables, disease conditions, specialty
of the physician prescribing the ﬁrst statin prescription, and the
presence of tests prior to start of therapy. RESULTS: Of the total
(N = 7440) patients, 65.2% were females and mean age was 49.7
years (S.D. = 9.4 years). White, non-Hispanic (42.7%), Hispanic
(32.7%), and Black, non-Hispanic (22.5%) formed the majority
